Starpharmaの時価総額
Starpharmaの時価総額は何ですか。
Starpharma Holdings Limitedの時価総額は150.91M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
ASXのセクタHealth Careにおける時価総額の企業と比べるStarpharma
Starpharmaは何をしますか。
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharmaと類似の時価総額
- Conns Incの時価総額は150.73M$です。
- Arbuthnot Banking PLCの時価総額は150.79M$です。
- Skipperの時価総額は150.83M$です。
- RM Secured Direct Lending Plcの時価総額は150.85M$です。
- Desert Mountainの時価総額は150.89M$です。
- Camellia Plcの時価総額は150.90M$です。
- Starpharmaの時価総額は150.91M$です。
- Medallionの時価総額は151.16M$です。
- Pix Transmissionsの時価総額は151.24M$です。
- Hostelworld Plcの時価総額は151.38M$です。
- NWF plcの時価総額は151.41M$です。
- Tudor Goldの時価総額は151.48M$です。
- Loop Insightsの時価総額は151.51M$です。